The interaction between the renin-angiotensin system and peroxisome proliferator activated receptors: A hypothesis including the participation of mitochondria in aging

Frontiers in Bioscience

Volumn 12, Issue 3, 2007, Pages 1049-1062

  De Cavanagh, Elena M V ^a   Piotrkowski, Barbara ^a   Fraga, Cesar G ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin; Mitochondria; Oxidative damage; Respiratory chain; Review

Indexed keywords

EID: 34249796699     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2125     Document Type: Article

References (160)

1. Gerstein H C, J. Pogue, J. F. Mann, E. Lonn, G. R. Dagenais, M. McQueen & S. Yusuf: The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 48, 1749-1755 (2005)
2. Poulter N R, H. Wedel, B. Dahlof, P. S. Sever, D. G. Beevers, M. Caulfield, S. E. Kjeldsen, A. Kristinsson, G. T. Mclnnes, J. Mehlsen, M. Nieminen, E. O'Brien, J. Ostergren & S. Pocock: Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 366, 907-913 (2005)
3. Williams B: Recent hypertension trials: implications and controversies. J Am Coll Cardiol 45, 813-827 (2005)
4. Yusuf S, P. Sleight, J. Pogue, J. Bosch, R. Davies & G. Dagenais: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342, 145-153 (2000)
5. de Cavanagh E M V, C. G. Fraga, L. Ferder & F. Inserra: Enalapril and captopril enhance antioxidant defenses in mouse tissues. Am JPhysiol 272, R514-518 (1997)
6. de Cavanagh E M V, F. Inserra, L. Ferder, L. Romano, L. Ercole & C. G. Fraga: Superoxide dismutase and glutathione peroxidase activities are increased by enalapril and captopril in mouse liver. FEBS Lett 361, 22-24 (1995)
7. de Cavanagh E M V, F. Inserra, J. Toblli, I. Stella, C. G. Fraga & L. Ferder: Enalapril attenuates oxidative stress in diabetic rats. Hypertension 38, 1130-1136 (2001)
8. de Cavanagh E M V, B. Piotrkowski, N. Basso, I. Stella, F. Inserra, L. Ferder & C. G. Fraga: Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. Faseb J 17, 1096-1098 (2003)
9. Beckman K B & B. N. Ames: The free radical theory of aging matures. Physiol Rev 78, 547-581 (1998)
10. Chance B, H. Sies & A. Boveris: Hydroperoxide metabolism in mammalian organs. Physiol Rev 59, 527-605 (1979)
11. DiMauro S & E. A. Schon: Mitochondrial respiratory-chain diseases. N Engl J Med 348, 2656-2668 (2003)
12. Miquel J: An update on the oxygen stress-mitochondrial mutation theory of aging: genetic and evolutionary implications. Exp Gerontol 33, 113-126 (1998)
13. de Cavanagh E M V, B. Piotrkowski & C. G. Fraga: Concerted action of the renin-angiotensin system, mitochondria, and antioxidant defenses in aging. Mol Aspects Med 25, 27-36 (2004)
14. Long D A, W. Mu, K. L. Price & R. J. Johnson: Blood vessels and the aging kidney. Nephron Exp Nephrol 101, e95-99 (2005)
15. Valdez L B, T. Zaobornyj, S. Alvarez, J. Bustamante, L. E. Costa & A. Boveris: Heart mitochondrial nitric oxide synthase. Effects of hypoxia and aging. Mol Aspects Med 25, 49-59 (2004)
16. Beckman J S, T. W. Beckman, J. Chen, P. A. Marshall & B. A. Freeman: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87, 1620-1624 (1990)
17. Castro L & B. A. Freeman: Reactive oxygen species in human health and disease. Nutrition 17, 161, 163-165 (2001)
18. Azzi A, K. J. Davies & F. Kelly: Free radical biology - terminology and critical thinking. FEBS Lett 558, 3-6 (2004)
19. Sies H: Oxidative stress: from basic research to clinical application. Am J Med 91, 31S-38S (1991)
20. Nicholls D G: Mitochondria and calcium signaling. Cell Calcium 38, 311-317 (2005)
21. Thomas D D, X. Liu, S. P. Kantrow & J. R. Lancaster, Jr.: The biological lifetime of nitric oxide: implications for the perivascular dynamics of NO and O2. Proc Natl Acad Sci USA 98, 355-360 (2001)
22. Brookes P S, E. P. Salinas, K. Darley-Usmar, J. P. Eiserich, B. A. Freeman, V. M. Darley-Usmar & P. G. Anderson: Concentration-dependent effects of nitric oxide on mitochondrial permeability transition and cytochrome c release. J Biol Chem 275, 20474-20479 (2000)
23. Cadenas E: Mitochondrial free radical production and cell signaling. Mol Aspects Med 25, 17-26 (2004)
24. Boveris A & E. Cadenas: Mitochondrial production of superoxide anions and its relationship to the antimycin insensitive respiration. FEBS Lett 54, 311-314 (1975)
25. Turrens J F & A. Boveris: Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem J 191, 421-427 (1980)
26. Ignarro L J: Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 30, 535-560 (1990)
27. Ghafourifar P & C. Richter: Nitric oxide synthase activity in mitochondria. FEBS Lett 418, 291-296 (1997)
28. Giulivi C, J. J. Poderoso & A. Boveris: Production of nitric oxide by mitochondria. J Biol Chem 273, 11038-11043 (1998)
29. Cadenas E & K. J. Davies: Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 29, 222-230 (2000)
30. Gadaleta M N, A. Cormio, V. Pesce, A. M. Lezza & P. Cantatore: Aging and mitochondria. Biochimie 80, 863-870 (1998)
31. Gredilla R & G. Barja: Minireview: the role of oxidative stress in relation to caloric restriction and longevity. Endocrinology 146, 3713-3717 (2005)
32. Gredilla R, A. Sanz, M. Lopez-Torres & G. Barja: Caloric restriction decreases mitochondrial free radical generation at complex I and lowers oxidative damage to mitochondrial DNA in the rat heart. Faseb J 15, 1589-1591 (2001)
33. Lopez-Torres M, R. Gredilla, A. Sanz & G. Barja: Influence of aging and long-term caloric restriction on oxygen radical generation and oxidative DNA damage in rat liver mitochondria. Free Radic Biol Med 32, 882-889 (2002)
34. Brookes P S, A. L. Levonen, S. Shiva, P. Sarti & V. M. Darley-Usmar: Mitochondria: regulators of signal transduction by reactive oxygen and nitrogen species. Free Radic Biol Med 33, 755-764 (2002)
35. Darley-Usmar V: The powerhouse takes control of the cell; the role of mitochondria in signal transduction. Free Radic Biol Med 37, 753-754 (2004)
36. Berger, J P T. E. Akiyama & P. T. Meinke: PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26, 244-251 (2005)
37. Schoonjans K, B. Staels & J. Auwerx: The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302, 93-109 (1996)
38. Scarpulla R C: Transcriptional activators and coactivators in the nuclear control of mitochondrial function in mammalian cells. Gene 286, 81-89 (2002)
39. Reddy J K & T. Hashimoto: Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annit Rev Nutr 21, 193-230 (2001)
40. Kelly L J, P. P. Vicario, G. M. Thompson, M. R. Candelore, T. W. Doebber, J. Ventre, M. S. Wu, R. Meurer, M. J. Forrest, M. W. Conner, M. A. Cascieri & D. E. Moller: Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression. Endocrinology 139, 4920-4927 (1998)
41. Nakatani T, N. Tsuboyama-Kasaoka, M. Takahashi, S. Miura & O. Ezaki: Mechanism for peroxisome proliferator-activated receptor-alpha activator-induced up-regulation of UCP2 mRNA in rodent hepatocytes. J Biol Chem 277, 9562-9569 (2002)
42. Takahashi M, N. Tsuboyama-Kasaoka, T. Nakatani, M. Ishii, S. Tsutsumi, H. Aburatani & O. Ezaki: Fish oil feeding alters liver gene expressions to defend against PPARalpha activation and ROS production. Am J Physiol Gastrointest Liver Physiol 282, G338-348 (2002)
43. Schiffrin E L, F. Amiri, K. Benkirane, M. Iglarz & Q. N. Diep: Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension 42, 664-668 (2003)
44. Tanaka T, J. Yamamoto, S. Iwasaki, H. Asaba, H. Hamura, Y. Ikeda, M. Watanabe, K. Magoori, R. X. loka, K. Tachibana, Y. Watanabe, Y. Uchiyama, K. Sumi, H. Iguchi, S. Ito, T. Doi, T. Hamakubo, M. Naito, J. Auwerx, M. Yanagisawa, T. Kodama & J. Sakai: Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sc U SA 100, 15924-15929 (2003)
45. Harman D: Aging: a theory based on free radical and radiation chemistry. J Gerontol 11, 298-300 (1956)
46. Schriner S E, N. J. Linford, G. M. Martin, P. Treuting, C. E. Ogburn, M. Emond, P. E. Coskun, W. Ladiges, N. Wolf, H. Van Remmen, D. C. Wallace & P. S. Rabinovitch: Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 308, 1909-1911 (2005)
47. Celi F S & A. R. Shuldiner: The role of peroxisome proliferator-activated receptor gamma in diabetes and obesity. Curr Diab Rep 2, 179-185 (2002)
48. Chawla A, J. J. Repa, R. M. Evans & D. J. Mangelsdorf: Nuclear receptors and lipid physiology: opening the X-files. Science 294, 1866-1870 (2001)
49. Evans R M, G. D. Barish & Y. X. Wang: PPARs and the complex journey to obesity. Nat Med 10, 355-361 (2004)
50. Kintscher U, C. J. Lyon & R. E. Law: Angiotensin II, PPAR-gamma and atherosclerosis. Front Biosci 9, 359-369 (2004)
51. Schiffrin E L: Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol 288, H1037-1043 (2005)
52. Sung B, S. Park, B. P. Yu & H. Y. Chung: Modulation of PPAR in aging, inflammation, and calorie restriction. J Gerontol A Biol Sci Med Sci 59, 997-1006 (2004)
53. Cabrero A, M. Alegret, R. M. Sanchez, T. Adzet, J. C. Laguna & M. V. Carrera: Increased reactive oxygen species production down-regulates peroxisome proliferator-activated alpha pathway in C2C12 skeletal muscle cells. J Biol Chem 277, 10100-10107 (2002)
54. Pardee K, J. Reinking & H. Krause: Nuclear hormone receptors, metabolism, and aging: what goes around comes around.Transcription factors link lipid metabolism and aging-related processes. Sci Aging Knowledge Environ 2004, re8 (2004)
55. Poynter M E & R. A. Daynes: Peroxisome proliferatoractivated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273, 32833-32841 (1998)
56. Aubert J, O. Champigny, P. Saint-Marc, R. Negrel, S. Collins, D. Ricquier & G. Ailhaud: Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells. Biochem Biophys Res Commun 238, 606-611 (1997)
57. Camirand A, V. Marie, R. Rabelo & J. E. Silva: Thiazolidinediones stimulate uncoupling protein-2 expression in cell lines representing white and brown adipose tissues and skeletal muscle. Endocrinology 139, 428-431 (1998)
58. Fleury C, M. Neverova, S. Collins, S. Raimbault, O. Champigny, C. Levi-Meyrueis, F. Bouillaud, M. F. Seldin, R. S. Surwit, D. Ricquier & C. H. Warden: Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat Genet 15, 269-272 (1997)
59. Gimeno R E, M. Dembski, X. Weng, N. Deng, A. W. Shyjan, C. J. Gimeno, F. Iris, S. J. Ellis, E. A. Woolf & L. A. Tartaglia: Cloning and characterization of an uncoupling protein homolog: a potential molecular mediator of human thermogenesis. Diabetes 46, 900-906 (1997)
60. Negre-Salvayre A, C. Hirtz, G. Carrera, R. Cazenave, M. Troly, R. Salvayre, L. Penicaud & L. Casteilla: A role for uncoupling protein-2 as a regulator of mitochondrial hydrogen peroxide generation. Faseb J 11, 809-815 (1997)
61. Cho D H, Y. J. Choi, S. A. Jo & I. Jo: Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways. J Biol Chem 279, 2499-2506 (2004)
62. Newaz M A, K. Ranganna & A. O. Oyekan: Relationship between PPARalpha activation and NO on proximal tubular Na+ transport in the rat. BMC Pharmacol 4, 1 (2004)
63. Newaz M, A. Blanton, P. Fidelis & A. Oyekan: NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)alpha-mediated cardiovascular effects. Mutat Res 579, 163-171 (2005)
64. Lee M A, M. Bohm, M. Paul & D. Ganten: Tissue renin-angiotensin systems. Their role in cardiovascular disease. Circulation 87, IV7-13 (1993)
65. Skeggs L T, K. E. Lentz, J. R. Kahn & H. Hochstrasser: Kinetics of the reaction of renin with nine synthetic peptide substrates. J Exp Med 128, 13-34 (1968)
66. Brewster U C, J. F. Setaro & M A. Perazella: The renin-angiotensin- aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 326, 15-24 (2003)
67. Omura T, S. Kim, K. Takeuchi, H. Iwao & T. Takeda: Transforming growth factor beta 1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: effects of inhibition of the renin-angiotensin system. Cardiovasc Res 28, 1835-1842 (1994)
68. Tummala P E, X. L. Chen, C. L. Sundell, J. B. Laursen, C. P. Hammes, R. W. Alexander, D. G. Harrison & R. M. Medford: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation 100, 1223-1229(1999)
69. Touyz R M, F. Tabet & E. L. Schiffrin: Redoxdependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol 30, 860-866 (2003)
70. Griendling K K & M. Ushio-Fukai: Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept 91, 21-27 (2000)
71. Kimura S., G. X. Zhang, A. Nishiyama, T. Shokoji, L. Yao, Y. Y, Fan, M. Rahman, T. Suzuki, H. Maeta & Y. Abe: Role of NAD(P)H oxidase- and mitochondria-derived reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin II. Hypertension 45, 860-866 (2005)
72. Mollnau H, M. Wendt, K. Szocs, B. Lassegue, E. Schulz, M. Oelze, H. Li, M. Bodenschatz, M. August, A. L. Kleschyov, N. Tsilimingas, U. Walter, U. Forstermann, T. Meinertz, K. Griendling & T. Munzel: Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90, E58-65 (2002)
73. Touyz R M: Activated oxygen metabolites: do they really play a role in angiotensin II-regulated vascular tone? JHypertens 21, 2235-2238 (2003)
74. Henriksen E J & S. Jacob: Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol 196, 171 -179 (2003)
75. Rincon-Choles H, B. S. Kasinath, Y. Gorin & H. E. Abboud: Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy. Kidney Int Suppl 8-11 (2002)
76. Touyz R M & E. L. Schiffrin: Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52, 639-672 (2000)
77. Baylis C, K. Engels, A. Hymel & L. G. Navar: Plasma renin activity and metabolic clearance rate of angiotensin II in the unstressed aging rat. Mech Ageing Dev 97, 163-172 (1997)
78. Harada K, M. Ohmori & A. Fujimura: Vasoconstricting effect of angiotensin II in human hand veins: influence of aging, diabetes mellitus and hypertension. Hypertens Res 25, 683-688 (2002)
79. Thompson M M, T. T. Oyama, F. J. Kelly, T. M. Kennefick & S. Anderson: Activity and responsiveness of the renin-angiotensin system in the aging rat. Am J Physiol Regul Integr Comp Physiol 279, R1787-1794 (2000)
80. Wang M, G. Takagi, K. Asai, R. G. Resuello, F. F. Natividad, D. E. Vatner, S. F. Vatner & E. G. Lakatta: Aging increases aortic MMP-2 activity and angiotensin II in nonhuman primates. Hypertension 41, 1308-1316 (2003)
81. Ruiz-Ortega M, M. Ruperez, V. Esteban & J. Egido: Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 5, 73-79 (2003)
82. Puri P L, M. L. Avantaggiati, V. L. Burgio, P. Chirillo, D. Collepardo, G. Natoli, C. Balsano & M. Levrero: Reactive oxygen intermediates mediate angiotensin IIinduced c-Jun.c-Fos heterodimer DNA binding activity and proliferative hypertrophic responses in myogenic cells. J Biol Chem 270, 22129-22134 (1995)
83. Shih N L, T. H. Cheng, S. H. Loh, P. Y. Cheng, D. L. Wang, Y. S. Chen, S. H. Liu, C. C. Liew & J. J. Chen: Reactive oxygen species modulate angiotensin II-induced beta-myosin heavy chain gene expression via Ras/Raf/extracellular signal-regulated kinase pathway in neonatal rat cardiomyocytes. Biochem Biophys Res Commun 283, 143-148 (2001)
84. Larkin J E, B. C. Frank, R. M. Gaspard, I. Duka, H. Gavras & J. Quackenbush: Cardiac transcriptional response to acute and chronic angiotensin II treatments. Physiol Genomics 18, 152-166 (2004)
85. Casademont J & O. Miro: Electron transport chain defects in heart failure. Heart Fail Rev 7, 131-139 (2002)
86. Sanbe A, K. Tanonaka, R. Kobayasi & S. Takeo: Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction. J Mol Cell Cardiol 27, 2209-2222 (1995)
87. Sorescu D & K. K. Griendling: Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail 8, 132-140 (2002)
88. Kimura S, G. X. Zhang, A. Nishiyama, T. Shokoji, L. Yao, Y. Y. Fan, M. Rahman & Y. Abe: Mitochondriaderived reactive oxygen species and vascular MAP kinases: comparison of angiotensin II and diazoxide. Hypertension 45, 438-444 (2005)
89. Robertson A L, Jr. & P. A. Khairallah: Angiotensin II: rapid localization in nuclei of smooth and cardiac muscle. Science 172, 1138-1139(1971)
90. Sirett N E, A. S. McLean, J. J. Bray & J. I. Hubbard: Distribution of angiotensin II receptors in rat brain. Brain Res 122, 299-312 (1977)
91. Eggena P, J. H. Zhu, K. Clegg & J. D. Barrett: Nuclear angiotensin receptors induce transcription of renin and angiotensinogen mRNA. Hypertension 22, 496-501 (1993)
92. Eggena P, J. H. Zhu, S. Sereevinyayut, M. Giordani, K. Clegg, P. C. Andersen, P. Hyun & J. D. Barrett: Hepatic angiotensin II nuclear receptors and transcription of growth-related factors. J Hypertens 14, 961-968 (1996)
93. Booz G W, K. M. Conrad, A. L. Hess, H. A. Singer & K. M. Baker: Angiotensin-II-binding sites on hepatocyte nuclei. Endocrinology 130, 3641-3649 (1992)
94. Peters J, B. Kranzlin, S. Schaeffer, J. Zimmer, S. Resch, S. Bachmann, N. Gretz & E. Hackenthal: Presence of renin within intramitochondrial dense bodies of the rat adrenal cortex. Am J Physiol 271, E439-450 (1996)
95. Kudoh S, I. Komuro, T. Mizuno, T. Yamazaki, Y. Zou, I. Shiojima, N. Takekoshi & Y. Yazaki: Angiotensin II stimulates c-Jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats. Circ Res 80, 139-146 (1997)
96. Xia Y, L. M. Buja & J. B. McMillin: Activation of the cytochrome c gene by electrical stimulation in neonatal rat cardiac myocytes. Role of NRF-1 and c-Jun. J Biol Chem 273, 12593-12598 (1998)
97. Leary S C, D. Michaud, C. N. Lyons, T. M. Hale, T. L. Bushfield, M. A. Adams & C. D. Moyes: Bioenergetic remodeling of heart during treatment of spontaneously hypertensive rats with enalapril. Am J Physiol Heart Circ Physiol 283, H540-548 (2002)
98. Boveris A, G. D'Amico, S. Lores-Arnaiz & L. E. Costa: Enalapril increases mitochondrial nitric oxide synthase activity in heart and liver. Antioxid Redox Signal 5, 691-697 (2003)
99. Costa L E, P. La-Padula, S. Lores-Arnaiz, G. D'Amico, A. Boveris, M. L. Kurnjek & N. Basso: Long-term angiotensin II inhibition increases mitochondrial nitric oxide synthase and not antioxidant enzyme activities in rat heart. J Hypertens 20, 2487-2494 (2002)
100. Chen G, L. X. Lin, W. T. Zhuang, J. Yao, H. B. Huang, J. X. Liang, F. L. Zhang, J. P. Wen, L. T. Li, M. Lin & Q. M. Lin: [Effects of captopril on myocardial tissue energy metabolism and inflammation in rats with diabetic cardiomyopathy]. Di Yi Jun Yi Da Xue Xue Bao 24, 827-828, 831 (2004)
101. Tham D M, B. Martin-McNulty, Y. X. Wang, D. W. Wilson, R. Vergona, M. E. Sullivan, W. Dole & J. C. Rutledge: Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 11, 21-30 (2002)
102. Benkirane K, F. Amiri, Q. N. Diep, M. El Mabrouk & E. L. Schiffrin: PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol 290, H390-397 (2006)
103. Muller D N, J. Theuer, E. Shagdarsuren, E. Kaergel, H. Honeck, J. K. Park, M. Markovic, E. Barbosa-Sicard, R. Dechend, M. Wellner, T. Kirsch, A. Fiebeler, M. Rothe, H. Haller, F. C. Luft & W. H. Schunck: A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. Am J Pathol 164, 521-532 (2004)
104. da Cunha V, D. M. Tham, B. Martin-McNulty, G. Deng, J. J. Ho, D. W. Wilson, J. C. Rutledge, R. Vergona, M. E. Sullivan & Y. X. Wang: Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 178, 9-17 (2005)
105. Clasen R, M. Schupp, A. Foryst-Ludwig, C. Sprang, M. Clemenz, M. Krikov, C. Thone-Reineke, T. Unger & U. Kintscher: PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46, 137-143 (2005)
106. Tuck M L: Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system. Curr Hypertens Rep 7, 240-243 (2005)
107. Schupp M, L. D. Lee, N. Frost, S. Umbreen, B. Schmidt, T. Unger & U. Kintscher: Regulation of Peroxisome Proliferator-Activated Receptor {gamma} Activity by Losartan Metabolites. Hypertension (2005)
108. Heudes D, O. Michel, J. Chevalier, E. Scalbert, E. Ezan, J. Bariety, A. Zimmerman & B. Corman: Effect of chronic ANG I-converting enzyme inhibition on aging processes. I. Kidney structure and function. Am J Physiol 266, R1038-1051 (1994)
109. Ferder L, F. Inserra, L. Romano, L. Ercole & V. Pszenny: Decreased glomerulosclerosis in aging by angiotensin-converting enzyme inhibitors. J Am Soc Nephrol 5, 1147-1152 (1994)
110. Ma L J, S. Nakamura, J. S. Whitsitt, C. Marcantoni, J. M. Davidson & A. B. Fogo: Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 58, 2425-2436 (2000)
111. Ferder L F, F. Inserra & N. Basso: Advances in our understanding of aging: role of the renin-angiotensin system. Curr Opin Pharmacol 2, 189-194 (2002)
112. Bosch J, E. Lonn, J. Pogue, J. M. Arnold, G. R. Dagenais & S. Yusuf: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 112, 1339-1346 (2005)
113. Dahlof B, R. B. Devereux, S. Julius, S. E. Kjeldsen, G. Beevers, U. de Faire, F. Fyhrquist, T. Hedner, H. Ibsen, K. Kristianson, O. Lederballe-Pedersen, L. H. Lindholm, M. S. Nieminen, P. Omvik, S. Oparil & H. Wedel: Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 32, 989-997 (1998)
114. Pfeffer M A, E. Braunwald, L. A. Moye, L. Basta, E. J. Brown, Jr., T. E. Cuddy, B. R. Davis, E. M. Geltman, S. Goldman, G. C. Flaker & et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327, 669-677 (1992)
115. Park J. B., H. D. Intengan & E. L. Schiffrin: Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension. J Renin Angiotensin Aldosterone Syst 1, 40-45 (2000)
116. Ramachandran A, A. L. Levonen, P. S. Brookes, E. Ceaser, S. Shiva, M. C. Barone & V. Darley-Usmar: Mitochondria, nitric oxide, and cardiovascular dysfunction. Free Radic Biol Med 33, 1465-1474 (2002)
117. Schrauwen P & M. K. Hesselink: Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes 53, 1412-1417 (2004)
118. de Cavanagh E M V, J. E. Toblli, L. Ferder, B. Piotrkowski, I. Stella & F. Inserra: Renal Mitochondrial Dysfunction In Spontaneously Hypertensive Rats Is Attenuated By Losartan But Not By Amlodipine. Am J Physiol Regul Integr Comp Physiol (2006)
119. de Cavanagh E M V, B. Piotrkowski, J. Toblli, L. Ferder, F. Inserra & C. G. Fraga: Losartan ameliorates renal mitochondrial dysfunction in streptozotocin-induced diabetes and aging (abstract). Free Rad Biol Med 37 (suppl 1), s36 (2004)
120. Cefalu W T, Z. Q. Wang, A. D. Bell-Farrow, J. Collins, T. Morgan & J. D. Wagner: Caloric restriction and cardiovascular aging in cynomolgus monkeys (Macaca fascicularis): metabolic, physiologic, and atherosclerotic measures from a 4-year intervention trial. J Gerontol A Biol Sci Med Sci 59, 1007-1014 (2004)
121. Das M, I. Gabriely & N. Barzilai: Caloric restriction, body fat and ageing in experimental models. Obes Rev 5, 13-19 (2004)
122. Loupal G, A. Url, M. Skalicky & A. Viidik: Physical exercise retards the development of chronic nephropathy in the ageing rat as efficiently as food restriction does. Gerontology 51, 83-93 (2005)
123. Mattson M P, S. L. Chan & W. Duan: Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol Rev 82, 637-672 (2002)
124. Spindler S R: Rapid and reversible induction of the longevity, anticancer and genomic effects of caloric restriction. Mech Ageing Dev 126, 960-966 (2005)
125. Adelman, R, R. L. Saul & B. N. Ames: Oxidative damage to DNA: relation to species metabolic rate and life span. Proc Natl Acad Sci USA 85, 2706-2708 (1988)
126. Forster M J, B. H. Sohal & R. S. Sohal: Reversible effects of long-term caloric restriction on protein oxidative damage. J Gerontol A Biol Sci Med Sci 55, B522-529 (2000)
127. Leeuwenburgh C, P. Wagner, J. O. Holloszy, R. S. Sohal & J. W. Heinecke: Caloric restriction attenuates dityrosine cross-linking of cardiac and skeletal muscle proteins in aging mice. Arch Biochem Biophys 346, 74-80 (1997)
128. Zainal T A, T. D. Oberley, D. B. Allison, L. I. Szweda & R. Weindruch: Caloric restriction of rhesus monkeys lowers oxidative damage in skeletal muscle. Faseb J 14, 1825-1836 (2000)
129. Lambert A J, M. Portero-Otin, R. Pamplona & B. J. Merry: Effect of ageing and caloric restriction on specific markers of protein oxidative damage and membrane peroxidizability in rat liver mitochondria. Mech Ageing Dev 125, 529-538 (2004)
130. Lee J, B. P. Yu & J. T. Herlihy: Modulation of cardiac mitochondrial membrane fluidity by age and calorie intake. Free Radic Biol Med 26, 260-265 (1999)
131. Pamplona R, M. Portero-Otin, J, Requena, R. Gredilla & G. Barja: Oxidative, glycoxidative and lipoxidative damage to rat heart mitochondrial proteins is lower after 4 months of caloric restriction than in age-matched controls. Mech Ageing Dev 123, 1437-1446 (2002)
132. Chung M H, H. Kasai, S. Nishimura & B. P. Yu: Protection of DNA damage by dietary restriction. Free Radic Biol Med 12, 523-525 (1992)
133. Drew B, S. Phaneuf, A. Dirks, C. Selman, R. Gredilla, A. Lezza, G. Barja & C. Leeuwenburgh: Effects of aging and caloric restriction on mitochondrial energy production in gastrocnemius muscle and heart. Am J Physiol Regul Integr Comp Physiol 284, R474-480 (2003)
134. Sanz A, P. Caro, J. Ibanez, J. Gomez, R. Gredilla & G. Barja: Dietary restriction at old age lowers mitochondria! oxygen radical production and leak at complex I and oxidative DNA damage in rat brain. J Bioenerg Biomembr 37, 83-90 (2005)
135. Millet L, H. Vidai, F. Andreelli, D. Larrouy, J. P. Riou, D. Ricquier, M. Laville & D. Langin: Increased uncoupling protein-2 and -3 mRNA expression during fasting in obese and lean humans. J Clin Invest 100, 2665-2670 (1997)
136. Xiao H, D. Massaro, G. D. Massaro & L. B. Clerch: Expression of lung uncoupling protein-2 mRNA is modulated developmentally and by caloric intake. Exp Biol Med (Maywood) 229, 479-485 (2004)
137. Bauer M, A. C. Hamm, M. Bonaus, A. Jacob, J. Jaekel, H. Schorle, M. J. Pankratz & J. D. Katzenberger: Starvation response in mouse liver shows strong correlation with life-span-prolonging processes. Physiol Genomics 17, 230-244 (2004)
138. Lindholm L H, H. Ibsen, K. Borch-Johnsen, M. H. Olsen, K. Wachtell, B. Dahlof, R. B. Devereux, G. Beevers, U. de Faire, F. Fyhrquist, S. Julius, S. E. Kjeldsen, K. Kristianson, O. Lederballe-Pedersen, M. S. Nieminen, P. Omvik, S. Oparil, H. Wedel, P. Aurup, J. M. Edelman & S. Snapinn: Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 20, 1879-1886 (2002)
139. Parving H H, H. Lehnert, J. Brochner-Mortensen, R. Gomis, S. Andersen & P. Arner: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345, 870-878 (2001)
140. Deshayes F & C. Nahmias: Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16, 293-299 (2005)
141. Uemura H, N. Nakaigawa, H. Ishiguro & Y. Kubota: Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer. Curr Cancer Drug Targets 5, 307-323 (2005)
142. Cassis L A, D. E. Marshall, M. J. Fettinger, B. Rosenbluth & R. A. Lodder: Mechanisms contributing to angiotensin II regulation of body weight. Am J Physiol 274, E867-876 (1998)
143. Roth G S, D. K. Ingram & M. A. Lane: Caloric restriction in primates and relevance to humans. Ann N Y Acad Sci 928, 305-315 (2001)
144. DeLany J P, B. C. Hansen, N. L. Bodkin, J. Hannah & G. A. Bray: Long-term calorie restriction reduces energy expenditure in aging monkeys. J Gerontol A Biol Sci Med Sci 54, B5-11; discussion B12-13 (1999)
145. Engeli S, R. Negrel & A. M. Sharma: Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 35, 1270-1277 (2000)
146. Jalil J E, R. Ebensperger, J. Melendez, E. Acevedo, M. Sapag-Hagar, F. Gonzalez-Jara, A. Galvez, V. PerezMontes & S. Lavandero: Effects of antihypertensive treatment on cardiac IGF-1 during prevention of ventricular hypertrophy in the rat. Life Sci 64, 1603-1612 (1999)
147. Katie M & C. R. Kahn: The role of insulin and IGF-1 signaling in longevity. Cell Mol Life Sci 62, 320-343 (2005)
148. Wang A Y, A. W. Yu, C. W. Lam, L. M. Yu, P. K. Li, J. Goh & S. F. Lui: Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis. Am J Kidney Dis 39, 600-608 (2002)
149. Vitale C, G. Mercuro, C. Castiglioni, A. Cornoldi, A. Tulli, M. Fini, M. Volterrani & G. M. Rosano: Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 4, 6 (2005)
150. Chen S, Y. Noguchi, T. Izumida, J. Tatebe & S. Katayama: A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone. J Hypertens 14, 1325-1330 (1996)
151. Uresin Y, B. Erbas, M. Ozek, E. Ozkok & A. O. Gurol: Losartan may prevent the elevation of plasma glucose, corticosterone and catecholamine levels induced by chronic stress. J Renin Angiotensin Aldosterone Syst 5, 93-96 (2004)
152. Wu Y, J. P. Ouyang, Y. F. Zhou, K. Wu, D. H. Zhao & C. Y. Wen: Mechanism of improving effect of losartan on insulin sensitivity of non-insulin-dependent diabetes mellitus rats. Sheng Li Xue Bao 56, 539-549 (2004)
153. Coimbra C C, M. A. Garofalo, D. R. Foscolo, A. R. Xavier & R. H. Migliorini: Gluconeogenesis activation after intravenous angiotensin II in freely moving rats. Peptides 20, 823-827 (1999)
154. Furuhashi M, N. Ura, K. Higashiura, H. Murakami, M. Tanaka, N. Moniwa, D. Yoshida & K. Shimamoto: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42, 76-81 (2003)
155. Galletti F, P. Strazzullo, B. Capaldo, R. Carretta, F. Fabris, L. A. Ferrara, N. Glorioso, A. Semplicini & M. Mancini: Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS). J Hypertens 17, 439-445(1999)
156. Park S Y, G. H. Choi, H. I. Choi, J. Ryu, C. Y. Jung & W. Lee: Calorie restriction improves whole-body glucose disposal and insulin resistance in association with the increased adipocyte-specific GLUT4 expression in Otsuka Long-Evans Tokushima fatty rats. Arch Biochem Biophys 436, 276-284 (2005)
157. Boschmann M, J. Ringel, S. Klaus & A. M. Sharma: Metabolic and hemodynamic response of adipose tissue to angiotensin II. Obes Res 9, 486-491 (2001)
158. Folli F, C. R. Kahn, H. Hansen, J. L. Bouchie & E. P. Feener: Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100, 2158-2169 (1997)
159. Velloso L A, F. Folli, X. J. Sun, M. F. White, M. J. Saad & C. R. Kahn: Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 93, 12490-12495 (1996)
160. Umemura S, N. Nyui, K. Tamura, K. Hibi, S. Yamaguchi, M. Nakamaru, T. Ishigami, M. Yabana, M. Kihara, S. Inoue & M. Ishii: Plasma angiotensinogen concentrations in obese patients. Am J Hypertens 10, 629-633 (1997)